Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Ca
A phase 1/2 trial of Aldesleukin, Avelumab, Nivolumab in metastatic cancer and melanoma, run by Aulos Bioscience, Inc., now recruiting.
Overview
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer is a phase 1/2 interventional study registered as NCT05267626 by Aulos Bioscience, Inc., with 159 participants planned, started 2022-04-04 and due to reach its primary completion in 2027-02-28. Interventions recorded: AU-007, Aldesleukin, Avelumab, Nivolumab. Conditions listed: Advanced Solid Tumor, Metastatic Cancer, Cutaneous Melanoma, Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialQUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
Shares Avelumab, Nivolumab, Melanoma, Small-cell lung cancer.
- TrialStudy of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)
Shares Nivolumab, Melanoma, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Shares Nivolumab, Melanoma, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialAvelumab Program Rollover Study
Shares Avelumab, Metastatic cancer (cancer that has spread).
- TrialStudy BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression
Shares Nivolumab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Shares Nivolumab, Melanoma, Metastatic cancer (cancer that has spread).
- TrialA Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Rese
Shares Nivolumab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialStudy BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression
Shares Nivolumab, Metastatic cancer (cancer that has spread).